Slide 1: Orion Interim Report 1–3/2019
Orion Interim Report 1–3/2019
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January–March 2019
Highlights in January–March 2019
Slide 4: Marketing authorisation applications for darolutamide submitted in main markets
Marketing authorisation applications for darolutamide submitted in main markets 1 Marketing authorisation applications for the prostate cancer drug darolutamide 3 Net sales of Proprietary Products slightly declined from the previous year. Easyhaler, submitted in the main markets Dexdor and Simdax so
Slide 5: Key figures 1−3/2019
Key figures 1−3/2019 Net sales Operating profit Operating profit Cash flow per share margin before financial items 241 55 23% 0.40 MEUR (247) MEUR (70) (28%) EUR (0.39) -3% -21% +3% Interim Report 1–3/2019 ©Orion Corporation 25 April 2019 5
Slide 6: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 247 7 3 70 1 2 3 3 2 1 3 2 4 241 7 55 26 26 25 22 15 15 (1) Product sales without sales margin and product mix change and exchange rate effect (2) Product sales margin and product mix change but without exchange rate effect (3)
Slide 7: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1−3/2019 1−3/2018 1−3/2019 EUR million 11% +10% 90 -7% 6% 31% 80 70 60 +7% 50 -29% 40 34% 18% 30 -1% 20 Finland 10 Scandinavia Other Europe 0 North America Finland Scandinavia Other North Other Other markets Europe America markets Interim Report 1–
Slide 8: Net sales by business division
Net sales by business division EUR million 1−3/2019 -5% 140 2% 118 6% 120 111 -4% 9% 100 89 93 37% 80 60 +3% +21% 46% 40 +8% 21 20 20 15 12 5 4 0 Proprietary Products Specialty Proprietary Animal Fermion Contract Specialty Products Products Products Health manufacturing Animal Health & other Fermion
Slide 9: Best-selling pharmaceuticals 1–3/2019
Best-selling pharmaceuticals 1–3/2019 Net sales Change vs . Indication (EUR million) 1−3/2018 1. Asthma, COPD 26 +21% 2. Parkinson’s disease 21 -25% 3. Intensive care sedative 19 +10% 4. Acute heart failure 17 +16% 5. Animal sedatives 10 +15% Rheumatoid arthritis, inflammatory 6. Biosimilars bowel d
Slide 10: Proprietary Products
Proprietary Products
Slide 11: Easyhaler became the top proprietary product
Easyhaler became the top proprietary product EUR million 1−3/2019 +21% -25% 30 28 26 3% 3% +10% 25 22 21 19% +16% 24% 20 19 18 17 15 14 10 -52% 22% 5 29% 5 3 Parkinson's: Stalevo, Comtess & Comtan 0 Easyhaler Easyhaler Parkinson's Dexdor Simdax Precedex Dexdor family drugs Simdax Precedex 1−3/2019 1
Slide 12: Easyhaler product family will be a key source of growth in the next few years
Easyhaler product family will be a key source of growth in the next few years ● Budesonide-formoterol Easyhaler Sales, EUR million continued strong growth. 30 ● Product family total sales: +21% 25 ● Budesonide-formoterol Easyhaler: +35% 20 – Strong market position in some countries, 15 such as Swede
Slide 13: Orion is taking over the sale of its proprietary Parkinson's drugs in Europe
Orion is taking over the sale of its proprietary Parkinson’s drugs in Europe Breakdown of sales of Orion's branded Parkinson's drugs by market area 50 Sales, EUR million 45 40 2% 35 30 25 31% 20 34% 15 10 5 0 Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4 Q1 2014 2015 2016 2017 2018 2019 Europe 33% Japan
Slide 14: Sales of Dexdor intensive care sedative continued to grow – patent expired at the end of March
Sales of Dexdor intensive care sedative continued to grow – patent expired at the end of March Total value of European sedatives market: EUR 569 million (+3%) Sales, EUR million 20 18 12% 16 14 12% 12 65% 10 8 11% 6 4 2 0 Propofol EUR 368 million (+4%) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 15: Specialty Products
Specialty Products GRION Building well-being
Slide 16: Specialty Products: price competition continued especially in Finland
Specialty Products: price competition continued especially in Finland Development of net sales Net sales by region Net sales by product EUR 1−3/2019 1−3/2019 million -4% 80 68 10% 8% 70 65 60 12% 50 58% 26% 66% 40 +6% -8% 30 22 21 20 14 15 20% 10 0 Finland Scandinavia Eastern Finland Generic drugs E
Slide 17: In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs
In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1–3/2019) in Finland MEUR 106 (118) MEUR 28 (30) Market development Or
Slide 18: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−3/2019 Self-care Medicinal and non-medicinal products Reference priced products in hospital and pharmacy channels: EUR 676 million prescription Orion market share in EUR million drugs pharmacy 80 76 Orion 70 60 24 market share i
Slide 19: Research and development
Research and development
Slide 20: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targeted FGFR+VEGF
Slide 21: Progress in key development projects – new addition to portfolio: ODM-209
Progress in key development projects – new addition to portfolio: ODM-209 ● ODM-201/darolutamide for metastatic • ODM-209 for prostate and breast cancer: hormone-sensitive prostate cancer: – Orion has launched a Phase I clinical trial – Ongoing Phase III trial ARASENS in on the ODM-209 molecule. Thi
Slide 22: Orion's key business targets in 2019 (1–3)
Orion's key business targets in 2019 1. Preparation for the • Marketing authorisation applications commercialisation of submitted in main markets. darolutamide. ARASENS trial (metastatic prostate cancer) • With recruitment completed, the continues in order to expand the ARASENS trial continues as pl
Slide 23: Orion's key business targets in 2019 (4–6)
Orion's key business targets in 2019 4. Competitive product portfolio in • Orion's sales volume in Finland grew Specialty Products and faster than the market. strengthening of product launches. 5. Accelerating the growth of the • Easyhaler product family sales Easyhaler product family and increased
Slide 24: Current corporate responsibility themes at Orion
Current corporate responsibility themes at Orion ● Patient safety: New safety features for • We reduce the climate change prescription drugs required in all European impact of our own production. markets and implemented at Orion's production We have set ourselves an facilities. emissions target. ● O
Slide 25: Outlook
Outlook
Slide 26: Outlook for 2019 remains unchanged
Outlook for 2019 remains unchanged Net sales Orion estimates that in 2019 net sales will be slightly higher than in 2018 (net sales in 2018 were EUR 977 million). The estimated net sales include the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide. Oper
Slide 27: Orion calendar
Orion calendar Capital Markets Day Helsinki, 22 May 2019 Half-Year Financial Report 17/7/2019 Interim Report 1−9/2019 23/10/2019
Slide 28: Building well-being
Building well-being GRIoN Building well-being